STLN · Starling Oncology, Inc. · Insider Trading
The latest filing states the doubt was alleviated.
“the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $41,094 and an accumulated deficit of $283,700 at June 30, 2026, and a net loss of $12,281 and net cash provided by operations of $9,725 for the six months ended June 30, 2026. The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-21 | Hively Brad |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided. |
Common Stock
|
298,853 |
| 2026-08-14 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
12,000 |
| 2026-08-13 | Chernett Jorey |
10% Owner |
Sell↓
Filing footnotes — Call Option (STLN 19FEB27 $9C) (Direct)
The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. |
Call Option (STLN 19FEB27 $9C)
|
100 |
| 2026-07-27 | Hively Brad |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
27,108 |
| 2026-07-27 | McGeorge Anne |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
41,165 |
| 2026-07-27 | TZOUMAKAS KIMBERLY JO |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
29,116 |
| 2026-07-27 | Johnson Karen Marie |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
31,124 |
| 2026-07-27 | STOLPER MARK |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
31,124 |
| 2026-07-27 | Kaushal Mohit |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
33,133 |
| 2026-07-27 | Pacala Mark L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Common Stock
|
30,120 |
| 2026-07-21 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.27 to $5.28, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
18,000 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025. The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1. |
Common Stock
|
17,974 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Convert↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms. |
Stock Option (Right to Buy)
|
17,974 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025. The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1. |
Common Stock
|
5,478 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Convert↑
|
Common Stock
|
17,974 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Convert↑
|
Common Stock
|
5,478 |
| 2026-07-14 | Podnos Yale |
Chief Medical Officer |
Convert↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms. |
Stock Option (Right to Buy)
|
5,478 |
| 2026-07-10 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.82 to $5.90, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
15,000 |
| 2026-07-07 | TZOUMAKAS KIMBERLY JO |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSU award that was fully vested upon grant |
Common Stock
|
17,185 |
| 2026-07-07 | STOLPER MARK |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSU award that was fully vested upon grant. |
Common Stock
|
25,833 |
| 2026-06-23 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.02 to $5.04, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
18,000 |
| 2026-06-08 | Podnos Yale |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025. |
Common Stock
|
23,451 |
| 2026-06-04 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
12,000 |
| 2026-05-21 | Virnich Daniel |
Chief Executive Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |
Common Stock
|
23,058 |
| 2026-05-21 | Carter Robert Ross |
Chief Financial Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |
Common Stock
|
1,604 |
| 2026-05-21 | Podnos Yale |
Chief Medical Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |
Common Stock
|
1,805 |
| 2026-05-20 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
33,500 |
| 2026-05-19 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
5,000 |
| 2026-05-19 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
30,000 |
| 2026-04-16 | Kaushal Mohit |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. Price of $3.5005 was the volume weighted average selling price of all sales by the reporting person on April 16, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5050. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |
Common Stock
|
38,433 |
| 2026-04-14 | Kaushal Mohit |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5300. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |
Common Stock
|
57,286 |
| 2026-04-09 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
20,000 |
| 2026-03-27 | England Kristin |
Chief Administrative Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates |
Common Stock
|
55,743 |
| 2026-03-27 | Carter Robert Ross |
Chief Financial Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026 |
Common Stock
|
20,320 |
| 2026-03-27 | Podnos Yale |
Chief Medical Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026. |
Common Stock
|
16,173 |
| 2026-03-27 | Chernett Jorey |
10% Owner |
Buy↑
|
Common Stock
|
27,429 |
| 2026-03-27 | Carter Robert Ross |
Chief Financial Officer |
Award↓
Filing footnotes — Common Stock (Direct)
Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Common Stock
|
202,914 |
| 2026-03-27 | Virnich Daniel |
Chief Executive Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026. |
Common Stock
|
98,534 |
| 2026-03-27 | Langsam Jeffrey |
Chief Clinical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Common Stock
|
70,270 |
| 2026-03-27 | Virnich Daniel |
Chief Executive Officer |
Award↓
Filing footnotes — Common Stock (Direct)
Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Common Stock
|
670,608 |
| 2026-03-27 | Podnos Yale |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Common Stock
|
66,446 |
| 2026-03-26 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.11 to $3.19, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
50,000 |
| 2026-03-24 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.04 to $3.15, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
125,000 |
| 2026-03-20 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.35, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
25,000 |
| 2026-03-17 | Carter Robert Ross |
Chief Financial Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026. |
Common Stock
|
1,314 |
| 2026-03-17 | Virnich Daniel |
Chief Executive Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026. |
Common Stock
|
11,834 |
| 2026-03-17 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.39 to $3.49, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
75,000 |
| 2026-03-17 | Podnos Yale |
Chief Medical Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026. |
Common Stock
|
3,420 |
| 2026-03-16 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.43, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
60,985 |
| 2026-03-13 | Chernett Jorey |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.77 to $3.34, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
Common Stock
|
263,000 |